Insider Activity Spotlight: Arvinas Inc. and Chief Medical Officer Noah Berkowitz
Arvinas’ latest insider filing shows Chief Medical Officer Noah Berkowitz selling 6,435 shares on March 18, 2026 at $11.10 each. The trade was an automatic tax‑withholding sale triggered by the vesting of 25 % of the reporting person’s restricted stock units (RSUs) granted on March 18, 2024. Because the sale was required to satisfy withholding obligations, it is not a discretionary move that signals a shift in confidence or intent. For investors, the key takeaway is that the transaction is routine and unlikely to affect the company’s stock price or strategic trajectory.
Broader Insider Trends: What the Numbers Tell Us
When we look beyond Berkowitz, the company’s insider buying has been robust over the past months. The CEO, Randy Teel, and other senior officers—including the CFO, COO, and scientific leaders—have collectively purchased several hundred thousand shares. For instance, Teel added 147,179 shares on March 12, while the CFO Andrew Saik added 45,000 shares the same day. This sustained buying suggests that senior management believes Arvinas is undervalued relative to its pipeline potential, especially after the positive Phase 1 Parkinson’s data disclosed in early March. Conversely, a handful of insiders, including John Houston, have sold large positions; these sales are often driven by personal liquidity needs or portfolio rebalancing rather than a bearish outlook.
Implications for Investors and the Company’s Future
Arvinas’ recent clinical milestone—demonstrating protein reduction in cerebrospinal fluid for its PROTAC, ARV‑102—adds a layer of optimism to the stock’s narrative. The company’s market cap of roughly $789 million and a price‑earnings ratio of –9.17 reflect a still‑undervalued biotech that has yet to hit a positive earnings figure. The insider buying spree by top executives could be interpreted as a vote of confidence in the upcoming phase‑1b trial and the company’s broader neurodegenerative portfolio. For investors, this presents a potential catalyst: if the next data set confirms safety and efficacy, the stock could break out of its 52‑week low of $5.90. However, biotech ventures carry high risk, and any setbacks could quickly reverse the momentum.
Who Is Noah Berkowitz? A Profile of a CMO Who Trades Strategically
Noah Berkowitz’s insider activity is marked by a mix of large purchases and a few sales that align with vesting schedules or regulatory requirements. Over the last 12 months, he has bought over 210,000 shares, with the bulk of his purchases clustered around key dates—March 18, 2024 (RSU vesting) and May 9, 2025 (large option exercise). His most recent sale on February 13, 2026 at $11.89 was a strategic divestiture of 5,685 shares, likely tied to personal tax planning or portfolio diversification. The pattern suggests a long‑term view: Berkowitz keeps a sizable position in the company, indicating confidence in its scientific trajectory while using sales primarily for compliance or personal liquidity rather than reacting to market movements.
Bottom Line
Arvinas is navigating a pivotal phase of its clinical program with the backing of active insider buying and routine tax‑related sales. The current transaction by Noah Berkowitz is a routine RSU tax sale that does not alter the company’s strategic direction. For investors, the key signals come from the senior management’s continued buying and the promising neurodegenerative data. As the company moves toward its phase‑1b trial, watching insider sentiment and trading volume will provide early indications of how the market perceives the next wave of results.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-03-18 | Berkowitz Noah (Chief Medical Officer) | Sell | 6,435.00 | 11.10 | Common Stock |
